{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T03:53:32Z","timestamp":1788666812759,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.cyto.2023.156485","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T05:03:50Z","timestamp":1703912630000},"page":"156485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Macrophage migration inhibitory factor: A noval biomarker upregulates in myasthenia gravis and correlates with disease severity and relapse"],"prefix":"10.1016","volume":"175","author":[{"given":"Xiaoyu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0993-6994","authenticated-orcid":false,"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2023.156485_b0005","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia Gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2023.156485_b0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.cyto.2023.156485_b0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.autrev.2005.10.011","article-title":"T cell-mediated activation and regulation of anti-chromatin B cells","volume":"5","author":"Pag\u00e1n","year":"2006","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cyto.2023.156485_b0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1191\/096120398678920703","article-title":"Production of pathogenic antibodies: cognate interactions between autoimmune T and B cells","volume":"7","author":"Datta","year":"1998","journal-title":"Lupus"},{"key":"10.1016\/j.cyto.2023.156485_b0025","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cyto.2023.156485_b0030","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle. Nerve."},{"key":"10.1016\/j.cyto.2023.156485_b0035","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.cyto.2023.156485_b0040","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.autrev.2008.07.037","article-title":"MIF in autoimmunity and novel therapeutic approaches","volume":"8","author":"Stosic-Grujicic","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cyto.2023.156485_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108024","article-title":"Macrophage migration inhibitory factor (MIF): A multifaceted cytokine regulated by genetic and physiological strategies","volume":"233","author":"Sumaiya","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cyto.2023.156485_b0050","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41584-019-0238-2","article-title":"The immunobiology of MIF: function, genetics and prospects for precision medicine","volume":"15","author":"Kang","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.cyto.2023.156485_b0055","first-page":"42","article-title":"MIF promotes a differential Th1\/Th2\/Th17 inflammatory response in human primary cell cultures: Predominance of Th17 cytokine profile in PBMC from healthy subjects and increase of IL-6 and TNF-\u03b1 in PBMC from active SLE patients","volume":"324","author":"De la Cruz-Mosso","year":"2018","journal-title":"CellImmunol."},{"key":"10.1016\/j.cyto.2023.156485_b0060","first-page":"268","article-title":"Macrophage migration inhibitory factor in systemic lupus erythematosus","volume":"31","author":"Foote","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cyto.2023.156485_b0065","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cyto.2018.11.014","article-title":"Functional MIF promoter haplotypes modulate Th17-related cytokine expression in peripheral blood mononuclear cells from control subjects and rheumatoid arthritis patients","volume":"115","author":"Hern\u00e1ndez-Palma","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2023.156485_b0070","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13075-021-02619-3","article-title":"Isopsoralen ameliorates rheumatoid arthritis by targeting MIF","volume":"23","author":"Han","year":"2021","journal-title":"Arthritis. Res. Ther."},{"key":"10.1016\/j.cyto.2023.156485_b0075","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jneuroim.2005.07.019","article-title":"Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barr\u00e9 syndrome and experimental allergic neuritis","volume":"168","author":"Nicoletti","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.cyto.2023.156485_b0080","doi-asserted-by":"crossref","first-page":"E8421","DOI":"10.1073\/pnas.1712288114","article-title":"MIF and D-DT are potential disease severity modifiers in male MS subjects","volume":"114","author":"Benedek","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cyto.2023.156485_b0085","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.cellsig.2018.02.010","article-title":"LPS-mediated cell surface expression of CD74 promotes the proliferation of B cells in response to MIF","volume":"46","author":"Klasen","year":"2018","journal-title":"Cell. Signal."},{"key":"10.1016\/j.cyto.2023.156485_b0090","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.2174\/1389557515666150203144111","article-title":"The integral role of CD74 in antigen presentation, MIF signal transduction, and B cell survival and homeostasis","volume":"14","author":"Bucala","year":"2014","journal-title":"Mini. Rev. Med. Chem."},{"key":"10.1016\/j.cyto.2023.156485_b0095","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.4049\/jimmunol.1302209","article-title":"MIF promotes B cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70 signaling","volume":"192","author":"Klasen","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2023.156485_b0100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.cyto.2023.156485_b0105","doi-asserted-by":"crossref","first-page":"4337399","DOI":"10.1155\/2022\/4337399","article-title":"Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis","volume":"2022","author":"Zhou","year":"2022","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.cyto.2023.156485_b0110","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221122538","article-title":"Remission and relapses of myasthenia gravis on long-term tacrolimus: a retrospective cross-sectional study of a Chinese cohort","volume":"13","author":"Bi","year":"2022","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"10.1016\/j.cyto.2023.156485_b0115","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1007\/s10875-012-9781-1","article-title":"MIF, MIF alleles, and prospects for therapeutic intervention in autoimmunity","volume":"33","author":"Bucala","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.cyto.2023.156485_b0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/14728220903551304","article-title":"Autoimmune diseases: MIF as a therapeutic target","volume":"14","author":"Greven","year":"2010","journal-title":"Expert. Opin. Ther. Targets."},{"key":"10.1016\/j.cyto.2023.156485_b0125","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/14728222.2019.1656718","article-title":"Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus","volume":"23","author":"Bilsborrow","year":"2019","journal-title":"Expert. Opin. Ther. Targets."},{"key":"10.1016\/j.cyto.2023.156485_b0130","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/14728222.2017.1336227","article-title":"MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics","volume":"21","author":"Tilstam","year":"2017","journal-title":"Expert. Opin. Ther. Targets."},{"key":"10.1016\/j.cyto.2023.156485_b0135","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.drudis.2012.12.013","article-title":"Current developments of macrophage migration inhibitory factor (MIF) inhibitors","volume":"18","author":"Xu","year":"2013","journal-title":"Drug. Discov. Today."},{"key":"10.1016\/j.cyto.2023.156485_b0140","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/jcp.21346","article-title":"Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus","volume":"215","author":"Stosic-Grujicic","year":"2008","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.cyto.2023.156485_b0145","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1212\/NXI.0000000000000139","article-title":"Macrophage migration inhibitory factor promotes resistance to glucocorticoid treatment in EAE","volume":"2","author":"Ji","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.cyto.2023.156485_b0150","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1111\/bcp.14289","article-title":"Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours","volume":"86","author":"Mahalingam","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cyto.2023.156485_b0155","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/annrheumdis-2020-219803","article-title":"Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)","volume":"80","author":"Wallace","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2023.156485_b0160","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/13543780802636162","article-title":"Milatuzumab: a promising new agent for the treatment of lymphoid malignancies","volume":"18","author":"Mark","year":"2009","journal-title":"Expert. Opin. Investig. Drugs."},{"key":"10.1016\/j.cyto.2023.156485_b0165","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1096\/fj.201802433R","article-title":"Macrophage migration inhibitory factor regulates innate \u03b3\u03b4 T-cell responses via IL-17 expression","volume":"33","author":"Kim","year":"2019","journal-title":"FASEB. J."},{"key":"10.1016\/j.cyto.2023.156485_b0170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.expneurol.2017.06.021","article-title":"Macrophage migration inhibitory factor: A multifaceted cytokine implicated in multiple neurological diseases","volume":"301","author":"Leyton-Jaimes","year":"2018","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.cyto.2023.156485_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.816243","article-title":"Clinical Predictors of Relapse in a Cohort of Steroid-Treated Patients With Well-Controlled Myasthenia Gravis","volume":"13","author":"Su","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.cyto.2023.156485_b0180","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","article-title":"Clinical predictors for the prognosis of myasthenia gravis","volume":"17","author":"Wang","year":"2017","journal-title":"BMC. Neurol."},{"key":"10.1016\/j.cyto.2023.156485_b0185","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/cns.13468","article-title":"Immunotherapy choice and maintenance for generalized myasthenia gravis in China","volume":"26","author":"Zhang","year":"2020","journal-title":"CNS. Neurosci. Ther."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623003630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623003630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T10:11:02Z","timestamp":1736417462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466623003630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":37,"alternative-id":["S1043466623003630"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156485","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macrophage migration inhibitory factor: A noval biomarker upregulates in myasthenia gravis and correlates with disease severity and relapse","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"156485"}}